Bank Of Montreal Biocryst Pharmaceuticals Inc Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Bank Of Montreal holds 13,723 shares of BCRX stock, worth $106,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,723

Previous 13,723 -0.0%

Holding current value

$106,764

Previous $84,000 23.81%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $56,675 - $93,179	13,723 New	13,723 $84,000
Q4 2023 Feb 08, 2024	SELL	$4.98 - $6.77 $608,775 - $827,591	-122,244 Reduced 82.31%	26,279 $157,000
Q3 2023 Nov 01, 2023	BUY	$6.71 - $7.92 $712,098 - $840,510	106,125 Added 250.31%	148,523 $1.05 Million
Q2 2023 Aug 02, 2023	SELL	$6.96 - $8.81 $35,245 - $44,613	-5,064 Reduced 10.67%	42,398 $298,000
Q1 2023 Jun 13, 2024	BUY	$7.94 - $11.84 $310,930 - $463,654	39,160 New	39,160 $326,000
Q4 2022 Feb 01, 2023	SELL	$10.5 - $14.2 $16,096 - $21,768	-1,533 Reduced 3.13%	47,462 $544,000
Q3 2022 Nov 10, 2022	SELL	$10.79 - $14.81 $15,397 - $21,133	-1,427 Reduced 2.83%	48,995 $632,000
Q2 2022 Aug 11, 2022	SELL	$7.89 - $17.88 $44,681 - $101,254	-5,663 Reduced 10.1%	50,422 $531,000
Q1 2022 May 12, 2022	BUY	$11.56 - $19.76 $114,386 - $195,525	9,895 Added 21.42%	56,085 $922,000
Q4 2021 Feb 11, 2022	SELL	$11.18 - $15.46 $317,321 - $438,801	-28,383 Reduced 38.06%	46,190 $637,000
Q3 2021 Nov 12, 2021	BUY	$14.21 - $17.65 $309,863 - $384,875	21,806 Added 41.33%	74,573 $1.15 Million
Q2 2021 Aug 12, 2021	BUY	$9.5 - $17.24 $501,286 - $909,703	52,767 New	52,767 $831,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account